Impax unveils authorised generic Solodyn (Minocycline HCl) extended-release tablets in the market
21 February 2018 -

Pharmaceutical company Impax Laboratories Inc (NASDAQ:IPXL) reported on Tuesday the availability of the authorised generic version of Solodyn (minocycline HCl) extended-release tablets in 65 mg and 115 mg.

For the 12 months ending December 2017, Minocycline HCl extended-release tablets, 65 mg and 115 mg, had annual US sales of about USD148m according to IQVIA,

SOLODYN is indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older, added the company.

Impax is a specialty pharmaceutical company that markets its generic products through its Impax Generics division and its branded products through the Impax Specialty Pharma division.